UVI3003 is a high-affinity selective Pan-retinoid X receptor (RXR) full antagonist. Retinoid actions are predominantly mediated through the formation of various RAR and RXR isotype heterodimers that can act as either transcriptional repressors or activators. UVI3003 has been used as a tool to test the contribution of RXR to transactivation by a given RXR heterodimer. It was found to induce teratogenesis in zebrafish embryos and recently was found to inhibit A?42 aggregation.
Molecular Weight | 436.58 |
Formula | C28H36O4 |
CAS Number | 847239-17-2 |
Solubility (25°C) | DMSO 50 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related RAR/RXR Products |
---|
MSU-42011
MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist that potently inhibits the expression of iNOS as well as p-ERK protein levels. In addition, MSU-42011 has immunomodulatory and antitumor activities for cancer research. |
KCL-286
KCL-286 is an orally active retinoic acid receptor-beta (RAR-beta) agonist for studies related to spinal cord injury. |
XS-060
XS-060 is a potent anticancer agent and RXRα antagonist. |
BPA-B9
BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction. |
ER 50891 quarterhydrate
ER 50891 quarterhydrate is a potent antagonist of retinoic acid receptor α(RARα). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.